Radiopharm Theranostics【RADX】銘柄情報

個人投資家向けのプロ仕様のツール。

プレミアム

通貨

4.83

買値

4.01

売値

6.05

出来高

94,200

4.70 日の範囲 5.79

0.00 52 週間の範囲 0.00

前日終値

4.83

始値

4.94

時刻

4.81

最終取引時間

平均取引量 (3 か月)

財務取引量

US$ 467,680

VWAP

4.9648

Lantheus Increases to 12.16% shareholding in Radiopharm with US$5m (A$8m) Placement

Private placement to radiopharmaceutical industry leader Lantheus, for US$5.0 millionPlacement at A$0.060 per share, representing a premium of 150% to the last closing price of A$0.024Lantheus...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Radiopharm Announces Strategic Co-Development Partnership with Lantheus for Australia

RAD to advance the clinical development of Lantheus innovative radiopharmaceuticals in Australia Initial collaboration will focus on a Phase 1 imaging trialFinancial incentives to be paid to RAD...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

RAD 202 Receives Approval to Start Phase 1 Therapeutic Trial

Ethics approval received in Australia for the initiation of RAD’s Phase 1 therapeutic trial of 177Lu-RAD202 in Breast and Gastric CancersThe Phase 1 First-In-Human study is designed to assess the...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form EFFECT - Notice of Effectiveness

Form 424B3 - Prospectus [Rule 424(b)(3)]

期間 †	前日比	前日比 %	始値	高値	安値	平均出来高	VWAP
1	0	0	0	0	0	0	0	DR
4	0	0	0	0	0	0	0	DR
12	0	0	0	0	0	0	0	DR
26	0	0	0	0	0	0	0	DR
52	0	0	0	0	0	0	0	DR
156	0	0	0	0	0	0	0	DR
260	0	0	0	0	0	0	0	DR

RADX - Frequently Asked Questions (FAQ)

What is the current Radiopharm Theranostics share price?

The current share price of Radiopharm Theranostics is US$ 4.83

What is the 1 year trading range for Radiopharm Theranostics share price?

Radiopharm Theranostics has traded in the range of US$ 0.00 to US$ 0.00 during the past year

出来高
値上がり率
値下がり率

銘柄コード	株価	出来高
NVNINVNI Group Ltd	US$ 4.38 (193.96%)	366.98M
EVAXEvaxion Biotech AS	US$ 5.99 (64.56%)	55.41M
ELABPMGC Holdings Inc	US$ 3.0901 (56.07%)	76.48M
PCLAPicoCELA Inc	US$ 4.60 (49.35%)	3.75M
GOEVCanoo Inc	US$ 0.475 (43.94%)	282.22M
GODNUGolden Star Acquisition Corporation	US$ 3.11 (-75.82%)	17.51k
GODNGolden Star Acquisition Corporation	US$ 2.93 (-65.67%)	902.76k
NXTTNext Technology Holding Inc	US$ 1.37 (-54.93%)	2.56M
SGLYSingularity Future Technology Ltd	US$ 1.625 (-38.45%)	917.77k
WHLRLWheeler Real Estate Investment Trust Inc	US$ 90.11 (-38.07%)	8
ACONAclarion Inc	US$ 0.0557 (28.94%)	811.91M
NVNINVNI Group Ltd	US$ 4.38 (193.96%)	366.98M
RIMEAlgorhythm Holdings Inc	US$ 0.0357 (4.69%)	284.97M
GOEVCanoo Inc	US$ 0.475 (43.94%)	282.22M
NVDANVIDIA Corporation	US$ 142.62 (-3.12%)	232.88M

Invest-in-America 2月前

RADX: Whelp, for what it's worth, here's the new RADX iHub BOARD!!!! (They make cute DIAGNOSTIC --- & potentially THERAPEUTIC, as well --- Medical gadgets that can enter tiny, obscure, sites in our Homo sapiens BODIES; and then hopefully determine what-the-heck bad things are transpiring in there, & maybe fix them to boot!!!)

👍️0

市場データ

ニュース

投資ツール

市場

発見

Hot Features

Follow Feed

ライブオプションフロー

モニター

Radiopharm Theranostics Ltd (RADX)

個人投資家向けのプロ仕様のツール。

主要統計と詳細

RADX 最新ニュース

Lantheus Increases to 12.16% shareholding in Radiopharm with US$5m (A$8m) Placement

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Radiopharm Announces Strategic Co-Development Partnership with Lantheus for Australia

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

RAD 202 Receives Approval to Start Phase 1 Therapeutic Trial

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form EFFECT - Notice of Effectiveness

Form 424B3 - Prospectus [Rule 424(b)(3)]

Lantheus Increases to 12.16% shareholding in Radiopharm with US$5m (A$8m) Placement

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Radiopharm Announces Strategic Co-Development Partnership with Lantheus for Australia

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

RAD 202 Receives Approval to Start Phase 1 Therapeutic Trial

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

RADX - Frequently Asked Questions (FAQ)

ムーバー

RADX Discussion

最近閲覧した銘柄

会社情報

ビジネス

人気

アプリを入手

期間 †	前日比	前日比 %	始値	高値	安値	平均出来高	VWAP
1	0	0	0	0	0	0	0	DR
4	0	0	0	0	0	0	0	DR
12	0	0	0	0	0	0	0	DR
26	0	0	0	0	0	0	0	DR
52	0	0	0	0	0	0	0	DR
156	0	0	0	0	0	0	0	DR
260	0	0	0	0	0	0	0	DR

期間 †	前日比	前日比 %	始値	高値	安値	平均出来高	VWAP
1	0	0	0	0	0	0	0	DR
4	0	0	0	0	0	0	0	DR
12	0	0	0	0	0	0	0	DR
26	0	0	0	0	0	0	0	DR
52	0	0	0	0	0	0	0	DR
156	0	0	0	0	0	0	0	DR
260	0	0	0	0	0	0	0	DR

市場データ

ニュース

投資ツール

市場

発見

Hot Features

Follow Feed

ライブオプションフロー

モニター

Radiopharm Theranostics Ltd (RADX) 銘柄情報

Radiopharm Theranostics Ltd (RADX)

個人投資家向けのプロ仕様のツール。

主要統計と詳細

RADX 最新ニュース

RADX - Frequently Asked Questions (FAQ)

ムーバー

RADX Discussion

最近閲覧した銘柄

会社情報

ビジネス

人気

アプリを入手

期間 †	前日比	前日比 %	始値	高値	安値	平均出来高	VWAP
1	0	0	0	0	0	0	0	DR
4	0	0	0	0	0	0	0	DR
12	0	0	0	0	0	0	0	DR
26	0	0	0	0	0	0	0	DR
52	0	0	0	0	0	0	0	DR
156	0	0	0	0	0	0	0	DR
260	0	0	0	0	0	0	0	DR